Jordan Rubin, who had worked closely on the controversial investment in Valeant, is leaving the hedge fund. » Read More
Ross Muken, Evercore ISI managing director, discusses the pharmaceutical supply chain and profits. » Read More
Who gets how much of your healthcare dollar? CNBC's Meg Tirrell explains the drug pipeline.
Bill Ackman tells CNBC the past 12 months were the "worst period of performance" of his career, and the implosion of Valeant Pharmaceuticals was mostly to blame.
Mylan is trying to win over critics by issuing coupons to help consumers pay for its high-priced EpiPen. Don't be fooled, says Vox writer Sarah Kliff.
Wall Street likes health care despite its vulnerability to political headwinds and underperformance this year.
Presidential candidates are likely to keep targeting the healthcare sector, says O'Neil Securities' Kenneth Polcari.
Aggressive marketing tactics have led to the overall perception that the EpiPen is essential. NBC News reports.
If Mylan's CEO wants to lower the price of the EpiPen today, she could, Express Scripts' Dr. Steve Miller says.
Rep. Lloyd Doggett (D-Texas) discusses the EpiPen pricing saga and his views on greater price gouging in the drug industry with the "Fast Money" traders.
The FDA and Congress enabled Mylan to secure a monopoly on EpiPens and then jack up the prices, says this intellectual-property expert. So why can't they just end it?
Amid the Mylan EpiPen pricing saga, CNBC's Meg Tirrell looks at the drugs that may be next in line for controversial price hikes.
Sen. Amy Klobuchar (D-Minn.) discusses the call for the FTC to investigate Mylan and other "bad actors" over drug pricing rules.
Sen. Amy Klobuchar (D-Minn.) discusses legislation for EpiPen-like generic drugs to be more widely available, pricing controls and drug importation from Canada.
Sen. Amy Klobuchar (D-Minn.) discusses Mylan CEO Heather Bresch's comments on the EpiPen pricing controversy.
Steve Miller, Express Scripts chief medical officer, responds to Mylan's CEO Heather Bresch blaming the "middle men" for higher drug prices.
To blame the healthcare system is what Mylan CEO Heather Bresch told CNBC today in explaining why the price of her company's EpiPen has seen price hikes of 400%. CNBC's Meg Tirrell breaks down the pharma supply chain system.
There needs to be more transparency in drug pricing, and Mylan still has a lot of questions to answer, Sen. Charles Grassley said Thursday.
Get the best of CNBC in your inbox